The U.S. Food and Drug Administration recently approved Novartis’ Tafinlar (dabrafenib) with Mekinist (trametinib) for adjuvant treatment of melanoma with BRAF V600E and V600K mutations.
UCB’s Cimzia (certolizumab pegol) was recommended for approval by the European Committee for Medicinal Products (CHMP) for the treatment of adult patients with moderate-to-severe plaque psoriasis.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%